Biomarkers Can Detect Alzheimer’s in Living Patients
Alzheimer's disease can be accurately identified in living patients by collecting cerebrospinal fluid using a framework of three biomarkers.
Category: Dementias & Alzheimer’s
Dementias & Alzheimer’s
Latest
Dementias & Alzheimer’s
Latest
Quanterix Offers P-Tau 181 Kit for Detection and Study of Alzheimer’s Disease
Research suggests the biomarker could be critical to predicting Alzheimer’s disease progression and differentiating the disease from other disorders.
Dementias & Alzheimer’s
LatestCompanies Embark on Partnership for Neurodegenerative Disease Research
Quanterix will join forces with UmanDiagnostics to provide commercial access to an ultrasensitive single molecule array for the detection of neurofilament light in blood specimens.
Quest Offers Dementia Dx Panel for Treatable Forms of Cognitive Impairment
The test panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
Read More
Merck, Luminex to Develop CDx for Alzheimer’s
Luminex will be responsible for development, regulatory submission, and commercialization of the candidate companion diagnostic device, which will employ Luminex’s xMAP Technology.
Read MoreAmarantus BioScience Licenses LymPro Alzheimer’s Disease Diagnostic Blood Test
Amarantus BioScience Inc announced that it has licensed the LymPro Alzheimer’s Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences Inc.
Read More
Measuring Metabolism Can Predict the Progress of Alzheimer’s with 90% Accuracy, Study Says
Metabolic studies could lead to new therapies, says a Tel Aviv University researcher.
Read MoreExceeding Expectations
Vista Clinical Diagnostics offers the industry’s most advanced testing, and recently introduced a partnership program for smaller and medium-size labs. Davian Santana, president, and Nathan Hawkins, vice president. What if your favori
Read MoreAlzheimers Challenge 2012 Unveiled at Care Innovations Summit
he Alzheimer’s Challenge 2012 calls for inventive concepts to help improve the diagnostic identification and tracking of Alzheimer’s disease.
Read More
News Story #15302
Positive Early Results for Parkinson’s Treatment Michael J. Fox Harbor BioSciences, San Diego, which is investigating the use the company’s proprietary compound Triolex as a treatment for Parkinson’s disease (PD) with fund
Read MoreAchievement Reached In Diagnostic Blood Test For Alzheimer’s Disease
BiOasis announces completion of a project intended to produce proprietary monoclonal antibodies for its Cognitest blood test for Alzheimer’s disease.
Read MoreGE Presents Flutemetamol Data for Detection Of Alzheimers Link
Five Flutemetamol abstracts featured at the 2011 Human Amyloid Imaging meeting.
Read MoreAMT, Consortium To Develop Sanfilippo B Gene Therapy
Amsterdam Molecular Therapeutics to supply cGMP manufacturing to consortium led by Institut Pasteur for clinical development of therapy for rare genetic disorder in children (pictured: AMT CEO Jorn Aldag).
Read MoreRadient Pharmaceuticals Buying Provista Diagnostics
Radient Pharmaceuticals Corp (RPC) announced that it has entered into a letter of intent (LOI) to acquire Provista Diagnostics Inc (PDI), a Nevada corporation offering laboratory testing services that meet the Clinical Laboratory Improvement Act (CLIA) guidelines.
Read MoreGold Standard Diagnostics Signs Distribution Agreement with Axis-Shield
Gold Standard Diagnostics Inc (GSD) announced the execution of an agreement with Axis-Shield to distribute their proprietary assays in the US Market.
Read MoreVermillion Announces Issuance of Patent for Alzheimer’s Disease Diagnosis
Vermillion Inc, a molecular diagnostics company, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled “Biomarkers for Alzheimer’s disease” to the company.
Read MorePower3 Medical Makes New Findings During NuroPro Clinical Trials
Power3 Medical Products Inc announces that it has discovered new findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with widely used anti-dementia drugs.
Read MoreVenture Capital Group Invests in Start-Up Developing New Alzheimer’s Test
Foundation Venture Capital Group hopes to help to lower the number of people living with Alzheimer’s disease. The company has made an initial investment to Durin Technologies Inc., a start-up company developing a test that requires only a drop of blood to diagnose the disease.
Read More